Biotech Values

[Bickema]

EDIT - I see ..."A potential deal would value the biotech company at $3.1 billion, representing a 33% premium to Forty Seven stock's closing price on Thursday, Porges said in a report. He kept his market perform rating and 67 price target on Gilead stock."

Where are you getting the 30% premium? Is that in the article or is that just based on FTSV price AH? The article said approached by other suitors as well which would suggest higher than a 30% premium.

Also volume really picked up during the week and FTSV wasnt really hit on the FTSV news, it seems like this news got out earlier in the week.